Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter

Johnson & Johnson Vision Announces Launch of TECNIS Eyhance™ Toric II IOL with TECNIS Simplicity™ Delivery System, a Next-Generation Monofocal Intraocular Lens for Cataracts Patients with Astigmatism, in Europe TECNIS Eyhance™ Toric II IOL offers all the benefits associated with…

Johnson & Johnson Vision announced a series of new products and innovations at the 2019 American Academy of Ophthalmology (AAO) Annual Meeting in San Francisco, CA, USA. The company announced the US Food & Drug Administration (FDA) approval of the…

Leinfelden – Echterdingen, Germany March 19, 2021, VSY Biotechnology GmbH, an innovation-driven company with its progressive R&D activities in ophthalmology, visco supplementation in orthopedy and medical esthetics, announced today an agreement with WAKAMOTO PHARMACEUTICAL CO., LTD. (hereinafter refer to…

Central serous chorioretinopathy, commonly referred to as CSC, is a condition in which fluid accumulates under the retina, causing a serous (fluid-filled) detachment and vision loss. CSC most often occurs in young and middle-aged adults. For unknown reasons, men develop…

Traumatic injury to the central nervous system (CNS), spinal cord, and optic nerve is the primary cause of disability and the second largest cause of mortality worldwide. CNS injuries frequently result in catastrophic loss of sensory, motor, and visual skills,…

Topcon Healthcare Solutions and OphtAI, a joint venture specialized in Artificial Intelligence (AI) for ophthalmology, have announced a partnership to integrate OphtAI into Topcon’s Harmony Referral System, and provide eye care professionals with smarter access to AI services. OphtAI’s state-of-the-art…

South Korean ophthalmologists reported a fungal endophthalmitis outbreak after cataract surgery due to contaminated viscoelastic material. Researchers from the Department of Ophthalmology at Korea University Guro Hospital in Seoul, Korea, under the direction of Seong Woo Kim, MD, PhD, found…

According to recent market research by Allied Market Research, the global vision correction market was worth $20,302.8 million in 2021, and is expected to grow at a compound annual growth rate (CAGR) of 7.4% from 2022 to 2031, reaching $41,252.7…

Frontera Therapeutics has initiated a clinical trial for its gene therapy, FT-002, which is intended for the treatment of X-linked retinitis pigmentosa (XLRP). The first patient has already been given a dose of the gene therapy product. FT-002 is Frontera’s…

The FDA issued a Warning Letter1 on January 31, 2023, to RightEye, LLC, the manufacturer of the RightEye Vision System, for misbranding and adulteration. The RightEye Vision System is a Class II Nystagmograph medical device that has been cleared “recording,…